---
title: 'Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders
  for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial'
date: '2024-07-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39083288/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240731181850&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS AND RELEVANCE: Psoriasis treatment guidelines lack or provide
  inconsistent advice on patient stratification and treatment de-escalation. We present
  the first randomized trial providing evidence that, in patients with early complete
  skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing
  interval may control disease ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: Psoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease ...